Hikma Pharmaceuticals (LON:HIK) Hits New 12-Month Low – What’s Next?

Shares of Hikma Pharmaceuticals PLC (LON:HIK) reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as GBX 1,520 and last traded at GBX 1,531, with a volume of 305632 shares changing hands. The stock had previously closed at GBX 1,530.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Jefferies Financial Group restated a “buy” rating and set a GBX 2,360 price objective on shares of Hikma Pharmaceuticals in a research note on Friday, November 7th. Peel Hunt restated a “buy” rating and issued a GBX 2,170 price target on shares of Hikma Pharmaceuticals in a research report on Friday, November 7th. Berenberg Bank lowered their price objective on shares of Hikma Pharmaceuticals from GBX 2,510 to GBX 2,300 and set a “buy” rating for the company in a research report on Thursday, November 6th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Hikma Pharmaceuticals from GBX 2,500 to GBX 2,400 and set an “overweight” rating on the stock in a research note on Friday, November 7th. Five analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of GBX 2,416.

Hikma Pharmaceuticals Stock Performance

The company has a debt-to-equity ratio of 55.82, a current ratio of 1.66 and a quick ratio of 1.27. The company has a market cap of £3.38 billion, a P/E ratio of 9.15, a PEG ratio of 2.38 and a beta of 0.41. The stock has a fifty day moving average price of GBX 1,687.84 and a two-hundred day moving average price of GBX 1,825.33.

Insider Activity at Hikma Pharmaceuticals

In other news, insider Mazen Darwazah bought 315,000 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The shares were purchased at an average price of GBX 1,601 per share, with a total value of £5,043,150. Also, insider Said Darwazah bought 60,000 shares of the business’s stock in a transaction on Friday, November 7th. The stock was purchased at an average price of GBX 1,589 per share, with a total value of £953,400. Insiders have purchased a total of 462,214 shares of company stock worth $734,939,058 over the last ninety days. 18.15% of the stock is currently owned by corporate insiders.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.